Skip to main content

Table 1 Patient demographics

From: Yields and chondrogenic potential of primary synovial mesenchymal stem cells are comparable between rheumatoid arthritis and osteoarthritis patients

Group Patient number Age Sex CRP (mg/dl) ESR (mm) Medicine
       PSL (mg/day) DMARDs other than biologics Biologics
RA #1 62 F 0.05 46   MTX ADA
#2 67 F 0.49 29   MTX  
#3 43 F 0.2 26 2 MTX  
#4 48 F 0.06 39    
#5 42 F 0.3 15 16 MTX GLM
#6 80 F 4.2 71   TCR, SASP, BUC  
#7 76 M 5.9 111   MTX  
#8 62 F 0.5 38    
OA #9 66 F 0.02 10  
#10 72 F 0.42 28  
#11 75 F 0.07 14  
#12 74 F 0.1 40  
#13 74 F 0.03 9  
#14 71 F 0.02 14  
#15 78 F 0.12 18  
#16 81 F 0.03 18  
  1. Male vs. female was 1:7 in the RA group and 0:8 in the OA group, showing no significant difference (p = 0.99 by Mann-Whitney’s U test). The mean of age was 60 years old in the RA group, and 74 years old in the OA group: no significant difference between them (p = 0.06 by Mann-Whitney’s U test)
  2. CRP C-reactive protein, ESR erythrocyte sedimentation rate, PSL prednisolone, DMARDS disease-modifying antirheumatic drugs, MTX methotrexate, RA rheumatoid arthritis, ADA adalimumab, GLM golimumab, TCR tacrolimus,, SASP salazosulfapyridine, BUC bucillamine, OA osteoarthritis